The study will provide an economic evaluation of the incentives and rewards for pharmaceutical innovation in Europe, and its functioning within the Internal Market.
•Number: 590/PP/GRO/SME/16/F/121
The study will, in particular, analyse the effects of supplementary protection certificates (SPCs) for pharmaceutical uses (human and veterinary), and plant protection, data protection and market exclusivity for medicinal products for human use.
Evidence on the overall impact on availability and accessibility of pharmaceutical care for patients and the pressure on health systems across the European Union will be examined. The evidence and analysis provided by this study will hence support the policy making in those areas.
Period
Apr 2017 → Jan 2018
Work for
European Commission - DG Research and Innovation, Belgium